BeOne Medicines (NASDAQ:ONC) Earns Buy Rating from Truist Financial

Key Points

• Truist Financial reiterated its Buy rating on BeOne Medicines and raised its price target to $448 from $420, implying about 9.8% upside from the stock’s current price. Analysts’ average rating is “Moderate Buy,” with an average target of $434.39.
• BeOne’s latest quarterly results beat expectations: earnings were $3.64 per share versus $2.34 forecast, and revenue was $1.89 billion versus $1.76 billion expected. The company also raised its 2026 revenue guidance.
• The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma, which could expand the drug’s market if approved.

BeOne Medicines (NASDAQ:ONC - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at Truist Financial in a research report issued on Friday, Benzinga reports. They presently have a $448.00 price target on the stock, up from their prior price target of $420.00. Truist Financial's price target suggests a potential upside of 9.80% from the stock's current price.

A number of other equities research analysts also recently weighed in on the stock. Citigroup reaffirmed an "outperform" rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Nomura raised their target price on shares of BeOne Medicines from $454.75 to $484.91 and gave the stock a "buy" rating in a report on Thursday, August 6th. Guggenheim lifted their target price on BeOne Medicines from $420.00 to $430.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Zacks Research downgraded BeOne Medicines from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 5th. Finally, Wells Fargo & Company upped their target price on BeOne Medicines from $400.00 to $435.00 and gave the company an "overweight" rating in a report on Friday. Sixteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $434.39.

BeOne Medicines Stock Performance

BeOne Medicines stock traded up $20.77 during mid-day trading on Friday, reaching $408.02. The company's stock had a trading volume of 539,032 shares, compared to its average volume of 318,362. The firm has a market cap of $44.80 billion, a price-to-earnings ratio of 71.90 and a beta of 0.63. The business has a 50 day moving average price of $362.80 and a 200-day moving average price of $325.98. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. BeOne Medicines has a twelve month low of $253.95 and a twelve month high of $409.80.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, beating the consensus estimate of $2.34 by $1.30. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.76 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. Sell-side analysts predict that BeOne Medicines will post 8.99 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Chan Lee sold 2,666 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $360.00, for a total transaction of $959,760.00. Following the transaction, the senior vice president owned 812 shares in the company, valued at $292,320. This trade represents a 76.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Xiaodong Wang sold 38,287 shares of BeOne Medicines stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $349.10, for a total value of $13,365,991.70. Following the transaction, the insider owned 6,079 shares in the company, valued at approximately $2,122,178.90. This trade represents a 86.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 376,373 shares of company stock valued at $134,848,154. Corporate insiders own 6.19% of the company's stock.

Hedge Funds Weigh In On BeOne Medicines

Several hedge funds have recently made changes to their positions in the business. First Trust Advisors LP lifted its position in shares of BeOne Medicines by 91.9% in the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company's stock valued at $71,696,000 after acquiring an additional 115,601 shares in the last quarter. Jennison Associates LLC boosted its stake in BeOne Medicines by 102.1% in the 1st quarter. Jennison Associates LLC now owns 154,465 shares of the company's stock worth $45,871,000 after purchasing an additional 78,027 shares during the period. Renaissance Technologies LLC acquired a new position in BeOne Medicines in the 1st quarter worth approximately $19,438,000. Candriam S.C.A. boosted its stake in BeOne Medicines by 31.7% in the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company's stock worth $77,132,000 after purchasing an additional 62,470 shares during the period. Finally, SEB Asset Management AB purchased a new position in BeOne Medicines during the 1st quarter worth approximately $16,653,000. Institutional investors and hedge funds own 48.55% of the company's stock.

Key Stories Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q3 results topped estimates and revenue guidance was raised. BeOne reported adjusted EPS of $3.64 versus the $2.34 consensus and revenue of $1.89 billion versus $1.76 billion expected. The company also raised its 2026 revenue guidance, signaling stronger business expectations. BeOne Q3 earnings and guidance
• Positive Sentiment: FDA granted priority review to a BRUKINSA combination. The review concerns use in first-line mantle cell lymphoma; a label expansion could broaden the drug’s potential market if approved. FDA priority review for BRUKINSA
• Positive Sentiment: Analysts raised their price targets and maintained positive ratings. Barclays lifted its target to $446 with an “overweight” rating; Citizens JMP raised its target to $463 and kept “market outperform”; Wells Fargo raised its target to $435 and retained “overweight.” The revisions reflect improved analyst expectations, though targets are not guarantees of future performance. Barclays rating information Citizens JMP rating information Wells Fargo rating information

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.